Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3256-3264

  Denzel, Martin S ^a   Hebbard, Lionel W ^a   Shostak, Gregory ^b   Shapiro, Lawrence ^b   Cardiff, Robert D ^c   Ranscht, Barbara ^a  

^a BURNHAM INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VIRUS MIDDLE T ANTIGEN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC MODEL; GROWTH RATE; HISTOPATHOLOGY; HYPOXEMIA; HYPOXIA; KNOCKOUT MOUSE; LUNG; LUNG METASTASIS; MALE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TISSUE SECTION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADIPONECTIN; ANIMALS; ANTIGENS, VIRAL, TUMOR; APOPTOSIS; BLOOD VESSELS; CORNEAL NEOVASCULARIZATION; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; POLYOMAVIRUS; RECEPTORS, ADIPONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66149179123     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2661     Document Type: Article

References (41)

1. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-520 (Pubitemid 40799245)
2. Chen MP, Tsai JC, Chung FM, et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005;25:821-826 (Pubitemid 40463876)
3. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599 (Pubitemid 30353893)
4. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318-1323 (Pubitemid 38691756)
5. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-89 (Pubitemid 36091630)
6. Chen DC, Chung YF, Yeh YT, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006;237:109-114
7. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-1107 (Pubitemid 38368397)
8. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007;22:117-121
9. Wang Y, Lam JB, Lam KS, et al. Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006;66:11462-11470 (Pubitemid 46009979)
10. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
11. Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004;279:1304-1309 (Pubitemid 38082655)
12. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 2004;279:28670-28674 (Pubitemid 38900150)
13. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-737
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182 (Pubitemid 17231334)
15. Dilworth SM. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2002;2:951-956 (Pubitemid 37328896)
16. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
17. Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-2126 (Pubitemid 37310040)
18. Kouros-Mehr H, Bechis SK, Slorach EM, et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008;13:141-152
19. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 2008;20:164-170
20. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006;127:1041-1055
21. Brison O. Gene amplification and tumor progression. BiochimBiophys Acta 1993;1155:25-41. (Pubitemid 23163749)
22. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182:150-162 (Pubitemid 30022667)
23. Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3:85-94. (Pubitemid 128513222)
24. Namba R, Young LJ, Maglione JE, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005;7:R881-9.
25. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-961
26. Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG, Ranscht B. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 2008;68:1407-1416
27. Mulrane L, Rexhepaj E, Smart V, et al. Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: an initial report from the PredToxgroup. Exp Toxicol Pathol 2008;60:235-245
28. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-978 (Pubitemid 27314772)
29. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953 (Pubitemid 32756433)
30. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate anti-diabetic metabolic effects. Nature 2003;423:762-769 (Pubitemid 36735700)
31. Ellies LG, Fishman M, Hardison J, et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 2003;106:1-7. (Pubitemid 36750381)
32. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004;1:1384-1389 (Pubitemid 40022722)
33. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004;101:10308-10313 (Pubitemid 38924921)
34. Oshima RG, Lesperance J, Munoz V, et al. Angiogenic acceleration of Neu induced mammary tumor progression and metastasis. Cancer Res 2004;64:169-179 (Pubitemid 38114095)
35. Ranscht B, Dours-Zimmermann MT. T-cadherin, a novel cadherin cell adhesionmolecule in the nervous system lacks the conserved cytoplasmic region. Neuron 1991;7:391-402.
36. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451
37. Graham CH, Forsdike J, Fitzgerald CJ, Macdonald- Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999;80:617-623 (Pubitemid 29047530)
38. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63:1138-1143 (Pubitemid 36278449)
39. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 2006;25:2379-2392
40. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007;67:563-572 (Pubitemid 46192193)
41. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.